Pseudoxanthoma Elasticum (EC40): Complete ICD-11 Coding Guide

1. Introduction

Pseudoxanthoma elasticum (PXE) is a rare hereditary disease of connective tissue that affects the structural integrity of elastic fibers in multiple organ systems. This progressive genetic condition is characterized by abnormal calcification and fragmentation of elastic fibers, particularly in the skin, eyes, and cardiovascular system. The term "pseudoxanthoma" refers to the characteristic yellowish appearance of skin lesions, which resemble true xanthomas, although they are not related to lipid disorders.

The clinical importance of PXE lies in its multisystemic and progressive nature. Clinical manifestations can vary significantly among patients, ranging from cosmetic skin changes to serious cardiovascular and ophthalmologic complications that can significantly compromise quality of life. The condition predominantly affects the skin of the neck, armpits, and inguinal region, but the most serious complications involve the retina and blood vessels.

From an epidemiological perspective, PXE is considered a rare disease, affecting approximately one in every 25,000 to 50,000 individuals in the general population. The condition presents a predominantly autosomal recessive inheritance pattern, although autosomal dominant cases have been rarely described. The disease affects both sexes, with some studies suggesting a slight female predominance.

Precise coding of pseudoxanthoma elasticum is fundamental for multiple purposes: it enables appropriate epidemiological tracking of this rare condition, facilitates clinical and translational research, ensures appropriate reimbursement of diagnostic and therapeutic procedures, and enables adequate planning of health resources. Correct identification through code EC40 in ICD-11 is also essential for appropriate referral to specialists and for access to multidisciplinary follow-up programs necessary for optimal management of this complex condition.

2. Correct ICD-11 Code

The specific code for pseudoxanthoma elasticum in the International Classification of Diseases, 11th Revision (ICD-11) is EC40.

Code: EC40

Official description: Pseudoxanthoma elasticum

Parent category: null - Genetic disorders affecting collagen, elastin, or other dermal matrix proteins

Official definition: Pseudoxanthoma elasticum (PXE) is a hereditary connective tissue disease characterized by progressive calcification and fragmentation of elastic fibers in the skin, retina, and arterial walls.

This code is inserted in the chapter on developmental disorders of ICD-11, specifically in the section addressing genetic structural disorders of connective tissue. The classification recognizes PXE as a distinct diagnostic entity, differentiating it from other elastopathies and collagenoses. The location of this code reflects the primary genetic nature of the condition, in contrast to acquired or degenerative calcifications of elastic tissue.

The structure of ICD-11 allows greater diagnostic specificity compared to the previous version, facilitating accurate documentation of the clinical characteristics of this multisystemic condition. Code EC40 should be used when there is diagnostic confirmation of pseudoxanthoma elasticum, whether through clinical, histopathological, or genetic criteria. Appropriate coding requires clear understanding of the cardinal manifestations of the disease and its differentiation from other conditions affecting elastic fibers.

3. When to Use This Code

The EC40 code should be applied in specific clinical scenarios where there is clear evidence of pseudoxanthoma elasticum. Below, we present detailed practical situations:

Scenario 1: Characteristic cutaneous manifestations with histopathological confirmation A patient presents with typical cutaneous lesions in flexural areas, particularly on the neck and axillae, characterized by confluent yellowish papules that give an appearance of "chicken skin" or "plucked chicken skin." Skin biopsy reveals calcification and fragmentation of elastic fibers in the mid and deep dermis, confirmed by special stains such as Von Kossa or Verhoeff-Van Gieson. In this context, the EC40 code is appropriate even in the absence of initial ocular or cardiovascular manifestations, as histopathology confirms the diagnosis.

Scenario 2: Angioid streaks with family history A young patient, often in the second or third decade of life, presents with visual changes or is identified during routine ophthalmologic examination with characteristic angioid streaks on the retina. These streaks represent ruptures in the calcified Bruch membrane and appear as irregular lines radiating from the optic disc. When there is confirmed family history of PXE or subtle cutaneous manifestations present, the EC40 code is indicated, as angioid streaks are highly specific to this condition when they occur in young patients.

Scenario 3: Premature peripheral arterial disease with cutaneous findings A patient under 50 years of age develops intermittent claudication or other signs of peripheral arterial disease. Investigation reveals diffuse arterial calcification on imaging studies, and physical examination identifies subtle cutaneous changes compatible with PXE in flexural areas. The combination of premature vascular manifestations with dermatologic findings justifies the use of the EC40 code, especially when other causes of early vascular calcification have been excluded.

Scenario 4: Confirmed molecular genetic diagnosis An asymptomatic patient or one with minimal manifestations undergoes genetic testing due to positive family history. Molecular analysis identifies biallelic pathogenic mutations in the ABCC6 gene, confirming the diagnosis of PXE at the molecular level. Even in the absence of significant clinical manifestations at the time of evaluation, the EC40 code is appropriate, as genetic diagnosis establishes the presence of disease and allows initiation of preventive follow-up.

Scenario 5: Recurrent gastrointestinal bleeding with characteristic findings A patient presents with recurrent episodes of gastrointestinal bleeding, particularly from the upper digestive tract, with no obvious cause identified on initial endoscopic investigations. Subsequent evaluation reveals PXE cutaneous changes and angioid streaks on the retina. The bleeding is attributed to vascular fragility related to PXE. In this multisystemic context, the EC40 code is the appropriate primary diagnosis.

Scenario 6: Cardiovascular complications in a young patient with known PXE A patient with a previous diagnosis of PXE develops cardiovascular complications such as premature coronary artery disease, renal artery stenosis, or valvular calcification. During hospitalization or outpatient consultation for management of these complications, the EC40 code should be maintained as the underlying diagnosis, as cardiovascular manifestations are direct consequences of the underlying connective tissue disease.

4. When NOT to Use This Code

It is fundamental to recognize situations where code EC40 is not appropriate, avoiding incorrect coding and ensuring diagnostic specificity:

Cutaneous calcifications of other etiologies: Code EC40 should not be used for cutaneous calcifications related to other conditions such as calcinosis cutis associated with scleroderma, dermatomyositis, chronic renal insufficiency, or disorders of calcium and phosphorus metabolism. In these situations, the appropriate code should reflect the underlying disease causing secondary calcification.

Angioid streaks of other causes: Although angioid streaks are highly characteristic of PXE, they can occur in other conditions such as Paget's disease of bone, sickle cell anemia, Ehlers-Danlos syndrome, hyperphosphatemia, and ocular trauma. When angioid streaks occur in the context of these other diseases, without evidence of PXE, code EC40 should not be applied.

True xanthomas: The cutaneous lesions of PXE may superficially resemble xanthomas, but the latter are related to disorders of lipid metabolism and require different coding. True xanthomas occur in contexts of hypercholesterolemia, hypertriglyceridemia, or other dyslipidemias, and should be coded according to the underlying metabolic condition.

Other hereditary elastopathies: Conditions such as Ehlers-Danlos syndrome, cutis laxa, and other hereditary connective tissue diseases have their own specific codes in ICD-11. Although these conditions may share some features with PXE, such as connective tissue fragility, they have distinct genetic bases, clinical manifestations, and prognoses, requiring separate coding.

Isolated arterial calcification: The presence of arterial calcification, even when extensive or premature, does not automatically justify code EC40 in the absence of other manifestations of PXE. Atherosclerosis, Mönckeberg's sclerosis, arterial calcification associated with chronic kidney disease, and other causes of vascular calcification should be coded according to their specific etiology.

Unconfirmed suspicion: Code EC40 should not be used when there is only clinical suspicion without adequate confirmation. Situations where diagnostic investigation is incomplete or findings are ambiguous require provisional or symptomatic coding until definitive diagnosis is established through appropriate clinical, histopathological, or genetic criteria.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of pseudoxanthoma elasticum is based on a combination of clinical manifestations, histopathological findings, and when available, molecular genetic confirmation. To correctly apply the EC40 code, the healthcare professional must confirm the diagnosis through the following elements:

Dermatological evaluation: Carefully examine flexural areas, particularly the lateral and posterior neck, axillae, antecubital region, inguinal and popliteal areas. Look for clustered yellowish papules that give a "chicken skin" texture appearance. Affected skin frequently shows redundancy and loss of elasticity. Document the distribution, extent, and characteristics of cutaneous lesions.

Ophthalmological evaluation: A complete ophthalmological examination with dilated fundoscopy is essential. Look for angioid streaks, which appear as irregular lines, often with a radial pattern from the optic disc. Also assess for "peau d'orange" (orange peel appearance) at the posterior pole, choroidal neovascularization, and retinal hemorrhages. These findings reflect calcification of Bruch's membrane.

Cardiovascular evaluation: Perform detailed clinical history focusing on symptoms of peripheral arterial disease, angina at young age, difficult-to-control hypertension (which may suggest renal artery stenosis), and episodes of gastrointestinal bleeding. Consider vascular imaging studies when appropriate, including Doppler ultrasound, computed tomography, or angiography, which may reveal diffuse arterial calcification.

Histopathological confirmation: When indicated, skin biopsy of a characteristic lesion should be performed. The specimen should be processed with special stains for elastic fibers (Verhoeff-Van Gieson) and calcium (Von Kossa). Typical findings include fragmentation, calcification, and clumping of elastic fibers in the mid and deep dermis, with irregular basophilic appearance.

Molecular genetic testing: Analysis of the ABCC6 gene can confirm the diagnosis through identification of biallelic pathogenic mutations. This test is particularly useful in cases with atypical presentation, positive family history in asymptomatic individuals, or when definitive diagnostic confirmation is needed for genetic counseling.

Step 2: Verify specifiers

Although the EC40 code does not have formal subcategories in ICD-11, it is important to document the specific characteristics of the clinical presentation:

Severity of manifestations: Document whether the patient presents with mild disease (isolated cutaneous manifestations), moderate (ocular involvement without significant visual loss or asymptomatic vascular disease), or severe (visual loss, significant cardiovascular complications, recurrent bleeding).

Affected organ systems: Clearly specify which systems are involved: cutaneous, ophthalmological, cardiovascular, gastrointestinal. This information is crucial for planning multidisciplinary follow-up.

Age of onset: Record the age at which the first manifestations were identified, as this may have prognostic implications and relevance for family counseling.

Pattern of family inheritance: Document whether there is positive family history and the inheritance pattern observed, which is relevant for genetic counseling.

Step 3: Differentiate from other codes

Proper differentiation of PXE from other conditions is crucial for accurate coding:

Versus other elastopathies: Ehlers-Danlos syndrome is characterized by joint hyperextensibility and cutaneous fragility with abnormal scarring, but does not present with calcification of elastic fibers. Cutis laxa presents with redundant skin without the characteristic yellowish papules or calcification.

Versus metabolic calcifications: Disorders of calcium and phosphorus metabolism cause calcifications, but generally in different distribution and without the specific histopathological characteristics of PXE.

Versus premature atherosclerosis: Although PXE causes early vascular disease, the presence of characteristic cutaneous or ocular manifestations distinguishes it from other causes of premature atherosclerosis.

Step 4: Required documentation

For proper coding with EC40, medical documentation must include:

Mandatory checklist:

Detailed description of cutaneous lesions, including location and characteristics
Results of ophthalmological examination, specifically fundoscopy
Detailed family history of PXE or compatible manifestations
Results of skin biopsy, if performed, with histopathological description
Results of genetic testing, if available
Cardiovascular evaluation and assessment of other potentially affected systems
Differential diagnosis considered and excluded
Justification for PXE diagnosis based on established clinical criteria

Additional recommended elements:

Clinical photographs of cutaneous lesions
Fundoscopy images documenting angioid streaks
Vascular imaging studies when performed
Multidisciplinary follow-up plan established
Genetic counseling offered or planned

6. Complete Practical Example

Clinical Case

Initial presentation: A 28-year-old female patient seeks dermatological consultation reporting skin changes on her neck that she has been noticing progressively over the last five years. She describes the skin texture as "wrinkled" and "different," but denies associated symptoms such as pruritus or pain. During the history of present illness, she mentions that her mother has similar skin changes and experienced visual problems in the fourth decade of life, having undergone repeated ophthalmological treatments.

Evaluation performed:

On dermatological physical examination, multiple yellowish papules measuring 1-3mm in diameter are observed, grouped in the lateral and posterior regions of the neck, giving an appearance of "goose skin." The affected skin shows loss of elasticity and slightly redundant texture. Similar findings, although less pronounced, are identified in the bilateral axillae. There are no other significant cutaneous alterations.

Due to the suggestive family history and characteristic dermatological findings, the patient was referred for specialized ophthalmological evaluation. Fundoscopic examination revealed the presence of bilateral angioid streaks, radiating from the optic disc, more prominent in the right eye. An "orange peel" appearance was also observed in the macular region of both eyes. Visual acuity was preserved at the time of evaluation.

A skin biopsy of a representative lesion on the neck was performed. Histopathological analysis with hematoxylin-eosin staining showed fragmentation of elastic fibers in the middle and deep dermis. Von Kossa staining confirmed calcium deposits in the fragmented elastic fibers, and Verhoeff-Van Gieson staining clearly demonstrated the fragmentation and irregularity of elastic fibers.

The patient underwent cardiovascular evaluation, including Doppler ultrasound of the carotids and arteries of the lower extremities, which revealed mild arterial calcifications, unusual for her age, but without significant stenoses. Peripheral pulses were preserved and there were no symptoms of claudication.

Diagnostic reasoning:

The combination of characteristic cutaneous manifestations (yellowish papules in flexural areas), typical ophthalmological findings (angioid streaks in a young patient), histopathological confirmation (fragmentation and calcification of elastic fibers), and positive family history establishes the definitive diagnosis of pseudoxanthoma elasticum. The vascular findings are compatible with early manifestations of the disease, although they do not yet cause significant symptoms.

Justification for coding:

The code EC40 is fully justified in this case due to the presence of multiple major diagnostic criteria: typical dermatological manifestations in characteristic distribution, bilateral retinal angioid streaks, histopathological confirmation with calcification of elastic fibers, and family history compatible with autosomal recessive inheritance. The patient meets both clinical and histopathological criteria for PXE.

Step-by-Step Coding

Criteria analysis:

✓ Characteristic skin lesions in typical distribution
✓ Angioid streaks confirmed by ophthalmologist
✓ Skin biopsy with diagnostic findings
✓ Positive family history
✓ Compatible vascular manifestations (early arterial calcification)
✓ Exclusion of differential diagnoses

Code selected: EC40 - Pseudoxanthoma elasticum

Complete justification:

The code EC40 is appropriate because the patient presents the classic triad of manifestations of pseudoxanthoma elasticum: cutaneous, ophthalmological, and cardiovascular involvement. Histopathological confirmation eliminates any diagnostic doubt, demonstrating the characteristic alterations of elastic fibers with calcification. The age of presentation and family history are consistent with the typical pattern of the disease.

Applicable complementary codes:

Although EC40 is the primary diagnostic code, additional codes may be necessary to document specific manifestations or complications:

Code for angioid streaks if separate ophthalmological documentation is necessary
Code for arterial calcification if specific vascular treatment is instituted
Codes for future complications (retinal hemorrhage, cardiovascular events) when they occur

Documented follow-up plan:

The patient was counseled about the nature of the condition and the importance of multidisciplinary follow-up. A plan was established for annual ophthalmological evaluation with fundoscopy, periodic cardiovascular monitoring, and genetic counseling was offered considering future family planning. Appropriate documentation of code EC40 will facilitate access to this specialized follow-up and allow for appropriate epidemiological tracking.

7. Related Codes and Differentiation

Within the Same Category

Pseudoxanthoma elasticum (EC40) is classified within genetic disorders affecting collagen, elastin, or other dermal matrix proteins. Other codes in this category include various forms of Ehlers-Danlos syndrome, cutis laxa, and other hereditary elastopathies. Although they share the broad category of connective tissue disorders, each condition has distinct genetic, clinical, and histopathological characteristics.

The differentiation of PXE from other elastopathies is based primarily on the presence of calcification of elastic fibers, which is the defining characteristic of PXE but does not occur in other conditions in this category. Additionally, the pattern of cutaneous involvement (flexural areas with yellowish papules) and specific ophthalmologic manifestations (angioid streaks) are highly characteristic of PXE.

Differential Diagnoses

Ehlers-Danlos Syndrome (various EC codes): This condition presents with cutaneous and articular hyperextensibility, cutaneous fragility with abnormal "cigarette paper" scarring, and easy bruising. Unlike PXE, there is no calcification of elastic fibers, and cutaneous lesions have different distribution and characteristics. The inheritance pattern and genes involved are also distinct.

Cutis laxa (specific code in the EC category): Characterized by redundant and flaccid skin that hangs in folds, giving a prematurely aged appearance. Although it involves abnormalities of elastic fibers, it does not present the characteristic yellowish papules, calcification, or the typical ophthalmologic and cardiovascular manifestations of PXE.

Calcinosis cutis (various codes depending on etiology): Refers to calcium deposits in the skin from various causes, including scleroderma, dermatomyositis, chronic renal insufficiency, and calcium metabolism disorders. The distribution of calcifications is different, there is no involvement of elastic fibers in the manner characteristic of PXE, and systemic manifestations correspond to the underlying disease.

Xanthomas (codes for lipid disorders): These are lipid deposits in the skin associated with hyperlipidemias. Although they may have superficially similar appearance to PXE lesions, true xanthomas have different histologic composition (foam cells laden with lipids), occur in typical locations (tendons, eyelids), and are associated with lipid laboratory abnormalities.

Premature atherosclerosis (cardiovascular codes): Although PXE causes early vascular disease, premature atherosclerosis from other etiologies (familial hypercholesterolemia, diabetes, smoking) does not present with the cutaneous or ophthalmologic manifestations of PXE. The presence of isolated arterial calcification, without other PXE findings, does not justify the EC40 code.

Angioid streaks from other causes: May occur in Paget disease, sickle cell anemia, and ocular trauma. In these cases, the clinical context, absence of cutaneous manifestations of PXE, and findings of the underlying disease allow for differentiation. The appropriate code should reflect the primary condition causing the angioid streaks.

8. Differences with ICD-10

In the International Classification of Diseases, 10th Revision (ICD-10), pseudoxanthoma elasticum was coded as Q82.8 (Other specified congenital malformations of the skin) or, in some systems, as E83.5 (Disorders of calcium metabolism), depending on the clinical focus and local coding guidelines.

The transition to code EC40 in ICD-11 represents a significant improvement in diagnostic specificity and accuracy. Main changes include:

Greater specificity: Code EC40 is exclusive to pseudoxanthoma elasticum, eliminating the ambiguity of ICD-10 code Q82.8, which encompassed multiple different cutaneous malformations. This facilitates accurate epidemiological tracking and patient identification for clinical research.

More appropriate classification: The location of PXE within genetic disorders of connective tissue better reflects the pathophysiological nature of the condition, in contrast to the classification as "congenital malformation of the skin" in ICD-10, which did not adequately capture the multisystemic character of the disease.

Facilitates consistent coding: The existence of a specific code reduces coding variability among different professionals and institutions, which in ICD-10 could choose between Q82.8 or E83.5 depending on which manifestation was being emphasized.

Practical impact: For healthcare professionals, the change means that it is no longer necessary to use generic or ambiguous codes. For health systems, it allows better resource planning and identification of patients who need multidisciplinary specialized follow-up. For researchers, it facilitates the identification of patient cohorts for epidemiological studies and clinical trials. More precise coding can also positively impact reimbursement for diagnostic and therapeutic procedures specific to PXE.

9. Frequently Asked Questions

1. How is a definitive diagnosis of pseudoxanthoma elasticum made?

The diagnosis of PXE is established through a combination of clinical, histopathological, and when available, genetic criteria. Clinically, the presence of characteristic skin lesions (yellowish papules in flexural areas) associated with angioid streaks on the retina is highly suggestive. Histopathological confirmation through skin biopsy, demonstrating fragmentation and calcification of elastic fibers, is considered the gold standard. Genetic testing identifying biallelic mutations in the ABCC6 gene can definitively confirm the diagnosis, being particularly useful in cases with atypical presentation or for family counseling. It is not necessary that all systems be affected simultaneously to establish the diagnosis, especially in early phases of the disease.

2. Is treatment available in public health systems?

The management of pseudoxanthoma elasticum is primarily supportive and preventive, focusing on monitoring and treatment of complications. There is no specific cure for the condition. Multidisciplinary follow-up, including dermatology, ophthalmology, and cardiology, is generally available in public health systems. Ophthalmological treatments such as laser photocoagulation or intravitreal anti-VEGF injections for choroidal neovascularization are established procedures available in specialized centers. Cardiovascular management follows standard protocols for arterial disease. The availability of molecular genetic testing may vary between different regions and health systems, but is becoming progressively more accessible.

3. How long does treatment last?

Pseudoxanthoma elasticum is a chronic and progressive condition that requires lifelong follow-up. There is no specific "duration" of treatment, but rather a program of continuous monitoring. Annual ophthalmological evaluation is recommended for early detection of retinal complications, periodic cardiovascular monitoring according to initial findings and patient age, and dermatological follow-up as needed. Specific interventions, such as treatment of choroidal neovascularization or vascular procedures, are performed as clinically indicated. The goal is to detect and treat complications early, preserving long-term quality of life.

4. Can this code be used in medical certificates?

Yes, the code EC40 can and should be used in medical certificates when pseudoxanthoma elasticum is the relevant condition for work absence or functional limitation. For example, if a patient requires time off for ophthalmological procedures related to PXE complications, or if there are functional limitations due to cardiovascular manifestations, the code EC40 should be included in the documentation. However, it is important to remember that PXE itself, especially in early phases or with mild manifestations, may not cause significant functional disability. The need for a medical certificate should be based on specific functional limitations present, not simply on the presence of the diagnosis.

5. Which specialists should be involved in follow-up?

Optimal management of PXE requires a coordinated multidisciplinary approach. The dermatologist often makes the initial diagnosis and monitors cutaneous manifestations. The ophthalmologist is essential for annual retinal monitoring and treatment of ocular complications. The cardiologist or vascular specialist evaluates and monitors cardiovascular manifestations. The geneticist can be involved for molecular diagnostic confirmation and family counseling. Depending on specific complications, other specialists may be necessary, such as a gastroenterologist for gastrointestinal bleeding, or a nephrologist if there is renal involvement. Coordination among these specialists is fundamental for comprehensive patient care.

6. Is there a risk of transmission to children?

Pseudoxanthoma elasticum predominantly follows an autosomal recessive inheritance pattern. This means that both parents must carry a mutation in the ABCC6 gene for there to be a risk of disease transmission to their children. When both parents are carriers, there is a 25% chance that each child will be affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of not inheriting any mutation. Rare cases of autosomal dominant inheritance have been described. Genetic counseling is strongly recommended for affected individuals and their families, especially during family planning. Carrier genetic testing can be offered to at-risk relatives.

7. Can cutaneous manifestations be treated for aesthetic reasons?

The cutaneous changes of PXE are permanent and progressive, and there is no specific treatment that reverses the changes in elastic fibers. Cosmetic interventions such as plastic surgery or dermatological procedures may be considered in selected cases where there is significant skin redundancy causing important aesthetic discomfort. However, it is fundamental that patients understand that such procedures do not alter the progression of the underlying disease and that affected skin may have different scarring characteristics. The decision to proceed with aesthetic interventions should be individualized, considering realistic expectations and potential risks.

8. What is the long-term prognosis for patients with PXE?

The prognosis of pseudoxanthoma elasticum varies significantly among individuals, depending on the extent and severity of systemic involvement. Many patients have a normal life expectancy, although they may experience reduced quality of life due to ocular or cardiovascular complications. Vision loss due to choroidal neovascularization is a significant complication, but modern treatments such as anti-VEGF therapy have substantially improved the ophthalmological prognosis. Cardiovascular complications, including premature coronary artery disease, peripheral arterial disease, and gastrointestinal bleeding, can impact morbidity and mortality. Regular follow-up and proactive management of cardiovascular risk factors are essential to optimize long-term prognosis.

Conclusion

Precise coding of pseudoxanthoma elasticum using code EC40 in ICD-11 is fundamental for the appropriate management of this rare and complex condition. Clear understanding of diagnostic criteria, characteristic clinical manifestations, and differentiation from similar conditions enables healthcare professionals to apply this code appropriately. The increased specificity provided by ICD-11, compared to ICD-10, facilitates epidemiological tracking, clinical research, and health resource planning. Recognition of the multisystemic nature of PXE and implementation of coordinated multidisciplinary follow-up are essential to optimize clinical outcomes and quality of life for patients affected by this hereditary connective tissue condition.

External References

This article was prepared based on reliable scientific sources:

🌍 WHO ICD-11 - Pseudoxanthoma elasticum
🔬 PubMed Research on Pseudoxanthoma elasticum
🌍 WHO Health Topics
📊 Clinical Evidence: Pseudoxanthoma elasticum
📋 Ministry of Health - Brazil
📊 Cochrane Systematic Reviews

References verified on 2026-02-04

Pseudoxanthoma Elasticum

Share